Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting for Sarcoma

High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas

Summary:

The role of high-dose chemotherapy (HDCT) with PBSCT in the treatment of bone and soft-tissue sarcomas is not established. In total, 27 patients (15 female, median age at TPL 30.6 years (range: 13–59)) were analyzed (Ewing sarcoma family n=8, osteosarcoma n=6, MPNST (malignant peripheral nerve sheath tumor) n=4, synovial sarcoma n=3, liposarcoma n=2, leiomyosarcoma n=2, rhabdomyosarcoma n=1, meningosarcoma n=1). Following chemotherapy and surgery complete remission (CR) (n=9), partial remission (PR) (n=10), stable disease (SD) (n=2) and progressive disease (PD) (n=6) were reached prior HDCT. Different HDCT conditioning regimens were used. One patient died due to cardiac arrest after HDCT. Except hematologic side effects, no WHO grade III–IV complications were observed. Four patients died within 6 months due to PD, disease recurred in another seven patients and led to death, 15 patients are alive with/without disease. The median progression-free survival (PFS) is 12.0 months (range: 0–58), in nine CR patients median PFS is 25.8 months (range: 3–58). Although the role of HDCT in the treatment of sarcomas is not defined, a subgroup of patients who achieved CR before HDCT could benefit from this therapy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors in advanced soft tissue sarcoma: an analysis of 2185 patients treated with anthracycline-containing first-line regimens – a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 1999; 17: 150–157.

    Article  CAS  Google Scholar 

  2. Edmonson JH, Ryan LM, Blum RG et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269–1275.

    Article  CAS  Google Scholar 

  3. Antman KH, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276–1285.

    Article  CAS  Google Scholar 

  4. Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus CyVADic versus ifosfamide plus doxorubicin in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537–1545.

    Article  CAS  Google Scholar 

  5. Bui NB, Demaille MC, Chevreau C et al. qMAID vs MAID+25% in adults with advanced soft tissue sarcoma (STS): first results of a randomized study of the FNCLCC Sarcoma Group. Proc Am Soc Clin Oncol 1998; 17: 517a (abstr 1991).

    Google Scholar 

  6. Blay JY, van Glabbeke M, Nielsen OS et al. Five-year survivors in patients (pts) with advanced soft tissue sarcoma (ASTS) treated with doxorubicin: a study on 1742 patients (STBSG). Proc Am Soc Clin Oncol 1998; 17: 512a (abstr 1973).

    Google Scholar 

  7. Standard-Options-Recommandations Vol 1. Sarcome des Tissus Mous et Ostéosarcomes. Arnette Blackwell: Paris, France, 1995; pp 1–113.

  8. Demetri GD, Elias AD . Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: Implications for decision making in the clinic. Hematol Oncol Clin N Am 1995; 9: 765–785.

    Article  CAS  Google Scholar 

  9. Verweij J, Mouridsen HT, Nielsen OS et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncol Hematol 1995; 20: 193–201.

    Article  CAS  Google Scholar 

  10. Rosen G, Forscher C, Lowenbraun S et al. Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer 1994; 73: 2506–2511.

    Article  CAS  Google Scholar 

  11. Patel SR, Vadhan-Raj S, Papadopolous N et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies – dose–response and schedule dependence. J Clin Oncol 1997; 15: 2378–2384.

    Article  CAS  Google Scholar 

  12. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600–1608.

    Article  CAS  Google Scholar 

  13. Saeter G, Alvegard TA, Monge OR et al. Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma: a Scandinavian Sarcoma Group Phase II Study. Eur J Cancer 1997; 33: 1551–1558.

    Article  CAS  Google Scholar 

  14. Van Oosterom AT, Verweij J . New drugs for the treatment of sarcomas. Hematol Oncol Clin N Am 1995; 9: 909–925.

    Article  CAS  Google Scholar 

  15. Budd GT, Metch B, Balcerzak SP et al. High-dose cisplatin for metastatic soft tissue sarcoma. Cancer 1990; 65: 866–869.

    Article  CAS  Google Scholar 

  16. Jelic S, Kovcin V, Milanovic N et al. Randomised study of high-dose epirubicin versus high-dose epirubicin–cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997; 33: 220–225.

    Article  CAS  Google Scholar 

  17. Reichardt P, Tilgner J, Hohenberger P, Dorken B . Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adultpatients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998; 16: 1438–1443.

    Article  CAS  Google Scholar 

  18. Horowitz ME, Kinsella TJ, Wexler LH et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993; 11: 1911–1918.

    Article  CAS  Google Scholar 

  19. Burdach S, Jurgens H, Peters C et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993; 11: 1482–1488.

    Article  CAS  Google Scholar 

  20. Boulad F, Kernan NA, LaQuaglia MP et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998; 16: 1697–1706.

    Article  CAS  Google Scholar 

  21. Fagioli F, Aglietta M, Tienghi A et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol 2001; 20: 2150–2156.

    Article  Google Scholar 

  22. Sauerbrey A, Bielack S, Kempf-Bielack B et al. High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant 2001; 27: 933–937.

    Article  CAS  Google Scholar 

  23. Bokemeyer C, Franzke A, Hartmann JT et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80: 1221–1227.

    Article  CAS  Google Scholar 

  24. Elias AD, Ayash LJ, Wheeler C et al. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 1995; 15: 373–379.

    CAS  PubMed  Google Scholar 

  25. Dumontet C, Biron P, Bouffet E et al. High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. Bone Marrow Transplant 1992; 10: 405–408.

    CAS  PubMed  Google Scholar 

  26. Mesia R, Sola C, Lopez Pousa A et al. High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas. Rev Clin Esp 1994; 194: 960–965.

    CAS  PubMed  Google Scholar 

  27. Wiklund T, Saeter G, Strander H et al. The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery: the Scandinavian Sarcoma Group experience. Eur J Cancer 1997; 33: 357–361.

    Article  CAS  Google Scholar 

  28. Seynaeve C, Verweij J . High-dose chemotherapy in adult sarcomas: no standard yet. Semin Oncol 1999; 26: 119–133.

    CAS  PubMed  Google Scholar 

  29. Blay JY, Bouhour D, Ray-Coquard I et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 2000; 18: 3643–3650.

    Article  CAS  Google Scholar 

  30. Antman KH, Elias A . Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Oncol 1990; 17 (Suppl. 2): 7–15.

    CAS  PubMed  Google Scholar 

  31. Verweij J . Etoposide for soft tissue sarcomas: fact or fiction. Eur J Cancer 1997; 33: 1527–1528.

    Article  CAS  Google Scholar 

  32. Durand RE, Goldie JH . Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 1987; 71: 673–679.

    CAS  PubMed  Google Scholar 

  33. Rosti G, Ferrante P, Ledermann J et al. High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol Hematol 2002; 41: 129–140.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B Kasper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kasper, B., Lehnert, T., Bernd, L. et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 34, 37–41 (2004). https://doi.org/10.1038/sj.bmt.1704520

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704520

Keywords

This article is cited by

Search

Quick links